Multiple Immunotherapies Fail to Show Durable Survival on ASCO Value Framework

Source: Healio, December 2017

Only two of 23 indications for six FDA-approved immuno-oncology agents showed durable survival benefits under the revised ASCO value framework, according to study findings.
“There are [two] possible reasons for this,” Omer Ben-Aharon, MBA, MHA, from the department of management and health system management program at Bar-Ilan University in Israel, and colleagues wrote. “The first is that the public excitement concerning durable survival with immuno-oncology may lack sufficient supporting data. The second is that the ASCO value framework may be insufficiently calibrated to reward durable survival benefits.”
ASCO developed a conceptual framework to measure the value of cancer treatment options.